-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

Benzinga·05/09/2025 16:58:51
Listen to the news
Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $8 to $6.